Avalo Therapeutics, Inc. - 8-K Filing
Avalo Therapeutics reported Q1 2026 financial results with a net loss of $19.6 million and cash, cash equivalents, and short-term investments totaling $82 million as of March 31, 2026. The company announced positive topline Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa (HS), meeting primary endpoints with HiSCR75 response rates of 42.2% and 42.9%, respectively, at Week 16. Avalo also completed a public offering on May 7, 2026, raising $431.3 million in gross proceeds. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $AVTX